InsidersTradesSigma
申报总数
公司
▲ 买入（1 笔）
▼ 卖出（1 笔）
内部人交易记录
首席执行官已披露买入
1
已披露卖出
1
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Explore the detailed record of transactions filed by Boyle Kevin S. Sr., 首席执行官. Officer active across 2 companies, notably Ziopharm Oncology INC. Aggregated, 4 reports have been recorded. Breakdown: 1 buy · 1 sell. Total volume traded: €10k. History available since 30 August 2021. The latest transaction was disclosed on 1 September 2023 (Cession). Regulator: SEC (Form 4). The full history is free.
Companies and markets linked to Boyle Kevin S. Sr.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报4 总计
68,014 股@ US$0.140316.3% 占其流量Common StockSEC:0000950170-23-046504:0
18,750 股@ US$2.4183.7% 占其流量Common StockSEC:0000899243-22-030186:0
884 股@ US$1.40100.0% 占其流量Common StockSEC:0001209191-21-065138:0
标准退出：2022年2月14日 (T+90)
875,000 股0Common StockSEC:0001209191-21-054089:0
4 条申报中的 4 条
About Boyle Kevin S. Sr.
Kevin S. Boyle Sr. is the Chief Executive Officer of ZioPharm Oncology Inc. As CEO, he is responsible for the strategic direction of the company, overseeing operations and growth initiatives. His leadership is essential for the organization's success.
